Victoria Socha
Articles by Victoria Socha
CERTAIN registry data were used to assess age-related differences in outcomes among pediatric kidney transplant recipients.
Researchers studied the clinical relevance of allograft microvascular inflammation in kidney transplantation.
Development of a transplant morbidity gene panel highlights how genetic testing could open the door to personalized care.
Researchers studied outcomes of transplant recipients who received kidneys from toxoplasma-positive versus negative donors.
A study examined an association between hyperglycemic crises at diabetes diagnosis and a higher risk of developing CKD.
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
A trial assessed an acellular tissue engineered vessel (ATEV) compared to autologous arteriovenous fistula for hemodialysis.
Pegcetacoplan achieved significant reductions in proteinuria and C3c staining and stabilized eGFR in patients with C3G.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
Treatment of IgA nephropathy with felzartamab led to sustained proteinuria reduction and reduced eGFR decline.
BAFF and APRIL inhibitor atacicept reduced UPCR, hematuria, and Gd-IgA1 and stabilized eGFR in patients with IgAN.
A study examined the effects of semaglutide in patients with overweight/obesity and albuminuria CKD without T2D.
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD,
Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.
A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.